Gyre Therapeutics, Inc. - Common Stock (GYRE)

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Gyre Therapeutics just reported results for the second quarter of 2024.

Gyre Therapeutics just reported results for the first quarter of 2024.

Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.

We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.

Some Nasdaq stocks are soaring in 2024, but these five charts are down by 40% or more. Are any of these struggling stocks actually good buys at a low price?

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.